Document is current
Any future updates will be listed below
-
Authors
Franz, Luise https://orcid.org/0009-0000-2806-6536
Rubil, Tihomir
Balázs, Anita
Overtus, Marie https://orcid.org/0009-0003-7490-9946
Kemnitz-Hassanin, Kristin
Govaerts, Cedric https://orcid.org/0000-0003-3218-3262
Mall, Marcus A. https://orcid.org/0000-0002-4057-2199
Hackenberger, Christian P. R. https://orcid.org/0000-0001-7457-4742
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (431232613)
Deutsche Forschungsgemeinschaft (392923329)
Deutsche Forschungsgemeinschaft (431232613)
Deutsche Forschungsgemeinschaft (450557679)
German Federal Ministry of Education and Research
- License Information
-
More Information
Article History
Received: 17 May 2024
Accepted: 13 March 2026
First Online: 17 April 2026
Competing interests
: M.A.M. reports grants or contracts from Boehringer Ingelheim, Enterprise Therapeutics, Vertex Pharmaceuticals, the German Federal Ministry of Research, Technology and Space (BMFTR) and the German Research Foundation (DFG), with payments made to the institution; fees for consulting or participation on an advisory board from Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Pari, Splisense and Vertex Pharmaceuticals; payment or honoraria for lectures from Boehringer Ingelheim and Vertex Pharmaceuticals; travel reimbursement received for participation in advisory board meetings for Boehringer Ingelheim and Vertex Pharmaceuticals.
